No products in the cart
Mod GRF 1-29 & Ipamorelin Blend (10mg)
Mod GRF (1-29) & Ipamorelin blend is Synthesized and Lyophilized in the USA.
Discount per Quantity
|Quantity||5 - 9||10 +|
FREE - 30ml bottle of bacteriostatic water
(Required for reconstitution)
FREE - USPS priority shipping
What is the Mod GRF (1-29) & Ipamorelin Peptide Blend?
Mod GRF (1-29) & Ipamorelin are two peptides reported to posess similar functions, and work synergistically. Together, these peptides have the potential to trigger growth hormone release and stimulate the growth hormone pulses. This increase may result in the physiological benefits associated with increased growth hormone release, such as improved growth, vitality, mental clarity, and overall health. Mod GRF (1-29) peptide is an analog of growth hormone-releasing hormone (GHRH). Similarly, Ipamorelin is suggested to act via binding to growth hormone secretagogue receptors. Generally, GRF has a short half-life that limits its therapeutic potential. However, GRF (1-29) has a modified structure with an apparent longer half-life and therefore better therapeutic potential. Likewise, Ipamorelin appears to have a high sensitivity to growth hormone receptors, leading to superior therapeutic outcomes. Mixing these peptides into a single blend may lead to a better growth hormone response. Research suggests that using the blend of Mod GRF (1-29) & Ipamorelin may lead to better outcomes than using either of these peptides alone. These outcomes may include improved memory, higher glucose control, enhanced post-workout recovery, lean muscle gain, and improved overall health.
Mod GRF 1-29 Specifications
Molecular Formula: C152H252N44O42
Molecular Weight: 3367.95 g/mol
PubChem: CID 56841945
CAS Number: 863288-34-0
Molecular Formula: C38H49N9O5
Molecular Weight: 711.85 g/mol
PubChem: CID 9831659
CAS Number: 170851-70-4
Mod GRF 1-29 & Ipamorelin – Research in Gastrointestinal Health
Research suggests that GH may have positive effects on inflammatory bowel disease (especially Crohn’s disease) and short bowel syndrome. Researchers report that “65% of patients receiving GH achieved clinical remission, compared to 20% treated with CTX alone.” GH acts via Vasoactive Intestinal Peptide (VIP) receptor VIPC1. This interaction allows GH to improve bowel motility and constipation, a major issue in inflammatory bowel disease.
Mod GRF 1-29 & Ipamorelin – Research in Cardiac Health
Myocardial Infarction (MI) leads to the scarring of cardiac tissues and reduces heart function (such as ejection fraction); Studies in animal models have suggested the benefits of GH, stimulating therapies in improving heart health following MI. GH analogs may accelerate heart tissue repair post-MI, reduce infarct size, improve cardiac ejection fraction, and improve overall cardiac health. The scientists reveal that “Through activation of GHS-R1a, secretagogues produced a positive inotropic effect on ischemic cardiomyocytes and protected them from I/R injury probably by protecting or recovering p-PLB (and therefore SR Ca2+ content) to allow the maintenance or recovery of normal cardiac contractility.”
Mod GRF 1-29 & Ipamorelin – Research in Bone Health
Issues associated with bone health, such as osteoporosis, are a major public health concern. Therapies such as bisphosphonates, monoclonal antibodies, and hormone therapies are approved methods for treating osteoporosis. These therapies are effective, but serious side effects limit their efficacy. In comparison, GH stimulating peptides such as Mod GRF (1-29) and Ipamorelin may become an inexpensive therapy with the potential to improve bone health with an excellent safety profile. Long term use of corticosteroids is one of the biggest risk factors for accelerated osteoporosis. Research in animal models suggests that GH-stimulating peptides such as Ipamorelin may completely halt the bone loss triggered by steroids. Moreover, it may trigger new bone formation and increase the Bone Mineral Density (BMD) by four-fold. An increase in BMD would improve bone quality and strength, and reduce the risk of osteoporosis complications such as fragility fractures.
Mod GRF 1-29 & Ipamorelin – Research in Muscle Growth
Research suggests that GH-secretagogues like Ipamorelin may inhibit the catabolic effects of glucocorticoids on muscles (such as muscle wasting). Mod GRF (1-29) & Ipamorelin peptide combination may have a high GH-receptor sensitivity and act via mechanisms including increased levels of Insulin-Like Growth Factor 1 (IGF-1), leading to better muscle gain. The potential benefits of this combination make it a valuable therapeutic target for corticosteroid-induced muscle wasting and can stimulate muscle gain post-workout.
Mod GRF 1-29 & Ipamorelin – Research in Blood Sugar Regulation
Diabetes is a condition involving almost all major organs and body systems. Better blood sugar regulation leads to improved morbidity and mortality associated with diabetes. Mod GRF (1-29) & Ipamorelin blend may lead to better diabetes control in various ways. Some research suggests that using GH-analogs may increase the number of beta-pancreatic cells leading to better insulin secretion. Calcium-driven channels mediate insulin secretion from pancreatic cells. GH-secretagogues such as Ipamorelin may trigger insulin release from pancreatic cells by acting on the pancreatic cells’ calcium channels. Therefore, this peptide combination has a therapeutic potential for diabetes management.
Mod GRF 1-29 & Ipamorelin – Research in Management of Postoperative Ileus
Postoperative Ileus (POI) is a common complication following intra-abdominal surgeries. Researchers suggest this peptide combination may significantly reduce the chances of POI and reduce the time to the first meal by approximately 12 hours.
Mod GRF 1-29 & Ipamorelin – Research in Thyroid Health
Thyroid dysfunction occurs concomitantly with growth hormone disturbances. This is especially true for conditions involving the pituitary gland, where thyroid dysfunction is also associated with GH deficiency. Researchers have noticed that individuals with thyroid insufficiency, when given GRF, appear to show a better response to their thyroid replacement.
Mod GRF 1-29 & Ipamorelin – Research in Mental Health
The Mod GRF (1-29) & Ipamorelin peptide combination may affect neurodegenerative conditions and general mental well-being. Research suggests that GH-stimulating therapies can lead to improved neurogenesis and can be a potential therapy for conditions such as dementia and Parkinson’s Disease. In addition, research has also suggested that the use of GH and GH-analogs may improve mental health indicators such as concentration, mental clarity, problem-solving abilities, and etc.
- Waelbroeck M, Robberecht P, Coy DH, Camus JC, De Neef P, Christophe J. Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist. Endocrinology. 1985 Jun;116(6):2643-9. doi: 10.1210/endo-116-6-2643. PMID: 2859987.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822.
- Denson LA, Kim MO, Bezold R, Carey R, Osuntokun B, Nylund C, Willson T, Bonkowski E, Li D, Ballard E, Collins M, Moyer MS, Klein DJ. A randomized controlled trial of growth hormone in active pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2010 Aug;51(2):130-9. doi: 10.1097/MPG.0b013e3181c992d6. PMID: 20453679; PMCID: PMC2910806.
- Ma Y, Zhang L, Edwards JN, Launikonis BS, Chen C. Growth hormone secretagogues protect mouse cardiomyocytes from in vitro ischemia/reperfusion injury through regulation of intracellular calcium. PLoS One. 2012;7(4):e35265. doi: 10.1371/journal.pone.0035265. Epub 2012 Apr 6. PMID: 22493744; PMCID: PMC3320867.
- Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000 Jun;165(3):569-77. doi: 10.1677/joe.0.1650569. PMID: 10828840.
- Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996.
- Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro Endocrinol Lett. 2004 Dec;25(6):403-6. PMID: 15665799.
- Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014 Dec;29(12):1527-34. doi: 10.1007/s00384-014-2030-8. Epub 2014 Oct 21. PMID: 25331030.
- Valcavi R, Jordan V, Dieguez C, John R, Manicardi E, Portioli I, Rodriguez-Arnao MD, Gomez-Pan A, Hall R, Scanlon MF. Growth hormone responses to GRF 1-29 in patients with primary hypothyroidism before and during replacement therapy with thyroxine. Clin Endocrinol (Oxf). 1986 Jun;24(6):693-8. doi: 10.1111/j.1365-2265.1986.tb01666.x. PMID: 3098458.
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.